Close Menu

A Memorial Sloan Kettering-led team tracks tumor genomic changes in individuals with advanced melanoma receiving the anti-PD-1 immune checkpoint treatment nivolumab. Using a combination of exome sequencing, transcriptome sequencing, and T-cell receptor sequencing, the researchers characterized tumor and microenvironment features before and after nivolumab treatment in 68 advanced melanoma patients, including 33 individuals who had already progressed on the CTLA-4-targeting drug ipilimumab.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.